Popular terms

[SEARCH]

Platelet topics
Growth Factor
Fibroblast
Nanoparticle
Autologous
Leukocytes
Circulation
Transforming Growth Factor
Therapeutical
Platelet Derived Growth Factor
Bone Morphogenetic Protein
Endothelial
Recombinant
Stem Cells
Respiratory System
Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Platelet patents



      
           
This page is updated frequently with new Platelet-related patent applications. Subscribe to the Platelet RSS feed to automatically get the update: related Platelet RSS feeds. RSS updates for this page: Platelet RSS RSS



Date/App# patent app List of recent Platelet-related patents
08/27/15
20150241530 
 Isolating mr magnetic field probes from external rf irradiation patent thumbnailnew patent Isolating mr magnetic field probes from external rf irradiation
An arrangement for carrying out dynamic magnetic field measurements in a mr imaging or mr spectroscopy apparatus comprises at least one magnetic field probe (2) comprising a mr active substance (4), means (8, 10) for pulsed mr excitation of said substance and means (8, 10) for receiving an mr signal generated by said substance. The magnetic field probe further comprises a radio frequency shield (12) against external high-frequency electromagnetic field irradiation substantially surrounding the magnetic field probe.
Skope Magnetic Resonance Technologies Gmbh


08/27/15
20150241444 
 Methods for detecting heparin/platelet factor 4 antibodies patent thumbnailnew patent Methods for detecting heparin/platelet factor 4 antibodies
Methods for determining the presence of heparin/platelet factor 4 antibodies in a sample suspected to contain heparin/platelet factor 4 antibodies are provided, along with apparatus suitable for performing the methods. The method depends upon a color visualization indicating the presence or absence of heparin/platelet factor 4 antibodies in the sample.
Akers Biosciences, Inc.


08/27/15
20150240490 
 Device for fixing a tile to a structure, for example a supporting structure or an intermediate structure of a building, and ceiling suspended from a structure patent thumbnailnew patent Device for fixing a tile to a structure, for example a supporting structure or an intermediate structure of a building, and ceiling suspended from a structure
A device for fixing a tile to a structure, for example a supporting structure or an intermediate structure of a building, the fixing device having a suspension comprised of a threaded rod and a safety hook, a first end of the threaded rod being arranged so as to be connected to the structure, the safety hook being made integral with a second end of the threaded rod by a nut system; a tube retained in the safety hook, and a fastening hook fixed by a rigid connection on a platelet, the platelet arranged so as to be fixed to one main face of the tile, the fastening hook extending in a direction substantially perpendicular to the platelet, a free end of said fastening hook being shaped so as to be placed resting on the tube. The invention also relates to an associated suspended ceiling and to making non-planar suspended ceilings..
Ober


08/20/15
20150232932 
 Ankrd26 as a marker for diagnosis of thrombocytopenias patent thumbnailAnkrd26 as a marker for diagnosis of thrombocytopenias
An in vitro method for diagnosing thrombocytopenia in a subject, the method includes the step of assessing the ankrd26 platelet expression in a biological sample from the subject, wherein a ankrd26 platelet expression is indicative of a thrombocytopenia. Also described is a kit for diagnosing a thrombocytopenia in a subject, which includes at least one ankrd26 nucleic acid probe or oligonucleotide or antibody for assessing the ankrd26 platelet expression in a biological sample from the subject..
Institut Gustave Roussy


08/20/15
20150232657 
 Composite fuel pipes patent thumbnailComposite fuel pipes
A fuel pipe for an aircraft having a wall made of a material including a matrix composed of an epoxy copolymer obtained through the reaction of a resin of the bisphenol a diglycidyl ether type with an amine hardener, and from 3 to 5% of an organically modified nanoclay by weight of the epoxy copolymer, the nanoclay including layered magnesium aluminum silicate platelets, and reinforcing fibers embedded in the matrix. In one example, the resin is a bisphenol a epichlorohydrin based resin, a phenol, 4,40-(1-methylethylidene) bis-polymer with (chloromethyl) oxirane; the nanoclay is provided in a 4% weight proportion to the epoxy copolymer, and is a montmorillonite; the amine hardener is an amidoamine..
Bombardier Inc.


08/20/15
20150231315 
 Blood component separation device patent thumbnailBlood component separation device
An object of the invention is to provide a blood component separation device that can keep the concentration of anticoagulant in a predetermined blood component to a constant level to minimize aggregation of a predetermined blood component (for example, aggregation of platelets). One aspect of the present invention is a blood component separation device that separates the predetermined blood component from the blood drawn from a blood donor while supplying to the blood an anticoagulant for preventing coagulation of the blood, where an anticoagulant ratio, or a ratio of an amount of the anticoagulant supplied in relation to the blood, is set according to a hematocrit value of the blood donor so that a concentration of the anticoagulant in the predetermined blood component becomes a predetermined value..
Terumo Kabushiki Kaisha


08/13/15
20150226756 
 Dual anti-platelet medication/aspirin response and reactivity test using synthetic collagen patent thumbnailDual anti-platelet medication/aspirin response and reactivity test using synthetic collagen
The present invention provides tests that measures functional platelet aggregation such as by using light transmission aggregometry assays (ltaas) or flow cytometry, using synthetic, self-assembling human type i collagen, methods of predicting and measuring an individual's platelet anti-platelet medication sensitivity and residual platelet activity status when the individual is on a dual anti-platelet therapy of aspirin and anti-platelet medication and kits useful in the assays and methods.. .
Jnc Corporation


08/13/15
20150225599 
 Silver nanoplate compositions and methods patent thumbnailSilver nanoplate compositions and methods
Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoparticle, such as nanoplates, silver nanoplates or silver platelet nanoparticles, and to the solutions and substrates prepared by the methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates.
Sienna Labs, Inc.


08/13/15
20150224173 
 Method of preparing a growth factor concentrate derived from human platelets patent thumbnailMethod of preparing a growth factor concentrate derived from human platelets
The invention relates to a method of preparing an intra-dermally, intra-articularly, sub-dermally or topically administrable growth factor concentrate derived from human platelets. The method comprises the steps of suspending human platelets in multiple electrolyte isotonic solution; snap-freezing the suspension; thawing the frozen suspension; and sterile-filtering the suspension.
Kasiak Research Pvt. Ltd.


08/06/15
20150221439 
 Plastic film having a high voltage breakdown patent thumbnailPlastic film having a high voltage breakdown
A stretched film includes a dispersion of at least one polyester and/or polycarbonate in a matrix of at least one polyester and/or polycarbonate different from the first polyester and/or polycarbonate, the percentage by weight of the dispersed polyester and/or polycarbonate in the dispersion being less than 50% and the dispersed polyester and/or polycarbonate being in the form of platelets. The stretched film can be used as a dielectric in a capacitor..
Dupont Teijin Films U.s. Limited Partnership


08/06/15
20150219677 

Methods and kits for measuring von willebrand factor


Methods and kits for measuring levels of von willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein ibα having at least two of a g233v, d235y and m239v mutations and an agent to detect a complex between the recombinant glycoprotein ibα and von willebrand factor.. .
Bloodcenter Research Foundation


08/06/15
20150218388 

Zinc-magnesium anticorrosion pigments, anticorrosion paint, and the production of said anticorrosion pigments


The present invention relates to platelet-shaped zinc-magnesium pigments, wherein the platelet-shaped zinc-magnesium pigments comprise the 40.8 to 67.8 mol % of zinc, 32.2 to 59.2 mol % of magnesium and 0 to 7 mol % of mn, li, be, y, sn, al, ti, fe, cu and mixtures thereof, based in each case on the total molar amount of the elements zn, mg, mn, be, y, li, sn, al, ti, fe and cu, where the molar percentages add up to 100 mol %, and the median thickness h50 of the pigments is less than 1 μm. The invention further relates to the use and production of these pigments..
Eckart Gmbh


08/06/15
20150218387 

Zinc-magnesium alloy anticorrosion pigments, anticorrosion paint, and the production of said anticorrosion pigments


The present invention relates to platelet-shaped anticorrosion pigments, wherein the platelet-shaped zinc-magnesium alloy pigments have a composition comprising 25.1 to 76.85 mol % of zn, 23 to 67.3 mol % of mg, 0.15 to 7.6 mol % of mn, be, y, li, sn and mixtures thereof, 0 to 5 mol % of al, ti, fe, cu and mixtures thereof, based in each case on the total molar amount of the elements zn, mg, mn, be, y, li, sn, al, ti, fe and cu, where the molar percentages add up to 100 mol %. The invention further relates to the use and production of these pigments..
Eckart Gmbh


08/06/15
20150218337 

Composite materials and their uses as well as methods for the preparation thereof


A reinforced composite material based on a polymer matrix with reinforcement particles embedded therein. The polymer matrix is based on a polymer with soft and hard domains, and the reinforcement particles comprise inorganic nano-platelets in the polymer matrix in a volume fraction in the range of 0.01%-50%, the inorganic nano-platelets have a thickness in the range of 0.3-50 nm, with the proviso that the largest length and width is at least twice as large as the thickness; as well as inorganic micro-platelets in a volume fraction in the range of 1%-90%, wherein the inorganic micro-platelets have a thickness in the range of 10 nm-100 μm, with the proviso that the largest length and width is at least twice as large as the thickness.
Eth Zurich


08/06/15
20150218249 

Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis


The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors, to prevent, inhibit, or ameliorate allograft rejection or arteriosclerosis in organisms that receive an organ transplant.. .
Vegenics Pty Limited


07/30/15
20150210551 

Graphite nanoplatelets and compositions


Disclosed are graphite nanoplatelets produced by a process which comprises thermal plasma expansion of intercalated graphite to produce expanded graphite followed by exfoliation of the expanded graphite, where the exfoliation step is selected from ultrasonication, wet milling and controlled caviation and where greater than 95% of the graphite nanoplatelets have a thickness of from about 0.34 nm to about 50 nm and a length and width of from about 500 nm to about 50 microns. The intercalated graphite is intercalated for example with a mixture of sulfuric and nitric acids.
Basf Se


07/30/15
20150209502 

Triple syringe and methods of making platelet-enriched plasma and use thereof


A triple syringe system that allows for either a larger volume of acp, or a larger combined output of prp (platelet rich plasma) and ppp (platelet poor plasma). The different outputs are based upon different centrifuge spin regimes.
Arthrex, Inc.


07/30/15
20150209496 

Blood bag system and cassette


A blood bag system includes a bc pooling bag for centrifugation of a buffy coat, a filter for removing white blood cells from a supernatant liquid transferred from the bc pooling bag, a platelet preserving bag for reserving the supernatant liquid that has passed through the filter, a first tube connecting the bc pooling bag and an inlet of the filter, a second tube connecting the platelet preserving bag and an outlet of the filter, and a cassette to be fixed in the centrifugation and separation apparatus. The first tube and the second tube are disposed within the cassette.
Terumo Kabushiki Kaisha


07/30/15
20150209495 

Blood bag system and cassette


A blood bag system includes a bc pooling bag for centrifugation of a buffy coat, a filter for removing white blood cells from a supernatant liquid transferred from the bc pooling bag, a platelet preserving bag for reserving the supernatant liquid that has passed through the filter, a first tube connecting the bc pooling bag and an inlet of the filter, a second tube connecting the platelet preserving bag and an outlet of the filter, and a cassette to be fixed in the centrifugation and separation apparatus. The first tube and the second tube are disposed within the cassette.
Terumo Kabushiki Kaisha


07/30/15
20150209389 

Methods of generating mesenchymal stem cells which secrete neurotrophic factors


A method of generating mscs which secrete neurotrophic factors (ntfs) comprising incubating a population of undifferentiated mesenchymal stem cells (mscs) in a differentiating medium comprising basic fibroblast growth factor (bfgf), platelet derived growth factor (pdgf), heregulin and camp.. .
Brainstorm Cell Therapeutics Ltd.


07/23/15
20150203819 

Production of red blood cells and platelets from stem cells


This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (mep), comprising differentiating a mep precursor cell into a mep in culture in the presence of an aryl hydrocarbon receptor (ahr) modulator. In some embodiments the ahr modulator is an ahr antagonist.
Trustees Of Boston University


07/23/15
20150203536 

Cd31 peptides


The present invention provides peptides corresponding to fragments of cd31 that inhibit platelet and leukocyte activation, and to their use in the treatment of thrombotic disease. These peptides find use as therapeutic agents in the treatment of inflammatory diseases and thrombotic diseases such as atherothrombosis, in particular when immobilised onto solid supports..
Assistance Publique - Hopitaux De Paris


07/23/15
20150202356 

Passive separation of whole blood


Described are systems, methods, and kits for compression sedimentation and whole blood separation. For example, a compression sedimentation system may include a compression stage configured to accept a flexible reservoir configured to contain a liquid mixture.
Halcyon Biomedical, Incorporated


07/23/15
20150202264 

Platelet activation and growth factor release using electric pulses


Methods and systems for releasing growth factors are disclosed. In certain embodiments, a blood sample is exposed to a sequence of one or more electric pulses to trigger release of a growth factor in the sample.
General Electric Company


07/16/15
20150198620 

Anti-platelet response and reactivity test using synthetic collagen


The present invention provides platelet aggregation tests using synthetic, self-assembling type i human collagen, methods of measuring an individual's platelet anti-platelet medication sensitivity and residual platelet activity status when the individual is on a an anti-platelet medication and kits useful in the assays and methods.. .
Jnc Corporation


07/16/15
20150196513 

Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent


Methods of treating and/or preventing a cardiovascular event in a patient, the method comprising orally administering a colchicine to a patient who is receiving concurrent treatment with at least one antiplatelet agent, thereby treating and/or preventing the cardiovascular event in the patient are provided.. .
Murray And Poole Enterprises Limited


07/09/15
20150194246 

Permanent magnet, motor, and generator


A permanent magnet includes: a composition expressed by a composition formula: rpfeqmrcutco100-p-q-r-t (r is at least one element selected from rare-earth elements, m is at least one element selected from zr, ti, and hf, 10.5≦p≦12.5 at %, 23≦q≦40 at %, 0.88≦r≦4.5 at %, 4.5≦t≦10.7 at %); and a metal structure containing a cell phase having a th2zn17 crystal phase, a cell wall phase, an m-rich platelet phase formed vertically to a c-axis of the th2zn17 crystal phase, and a cu-rich platelet phase formed along the m-rich platelet phase.. .
Kabushiki Kaisha Toshiba


07/09/15
20150191734 

Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression


The present invention is directed to constructs, compositions and methods for modulating platelet-type 12 lipoxygenase (12-lo) in adipose tissue in vivo. Specifically, the invention provides constructs encoding expression-inhibiting oligonucleic acids, e.g.
The Medical Research Fund At The Tel-aviv Sourasky Medical Center


07/09/15
20150191455 

Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto


Pyrazole derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.


07/09/15
20150191454 

Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto


Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..

07/09/15
20150190468 

Methods for creating and using platelet extracts


This invention provides processes for creating and stabilizing extracts of platelets possessing improved properties for tissue engineering and cell culture applications relative to other methods, that can be made without the use of freeze lysis, the resulting compositions, and methods for using them.. .

07/09/15
20150190253 

Coated devices and methods of making coated devices that reduce smooth muscle cell proliferation and platelet activity


The present invention relates generally to the maintenance of blow flood using drug eluting stents and/or other coated medical devices to increased length of time of blood flow. Further, the present invention relates to drug-releasing coated devices for reducing smooth muscle cell proliferation and platelet activity to further limit restenosis utilizing resveratrol and quercetin, polyphenols that are linked to the cardioprotection of red wine consumption.
Nanocopoeia, Inc.


07/02/15
20150185214 

Methods and kits for measuring von willebrand factor


Methods and kits for measuring levels of von willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein ibα having a combination of g233v, d235y and m239v mutations and an agent to detect a complex between the recombinant glycoprotein ibα and von willebrand factor.. .
The Medical College Of Wisconsin, Inc.


07/02/15
20150185210 

Platelet measurement reagent, platelet measurement reagent kit, and platelet measurement method


A reagent for measuring platelets comprising nile blue hydrogensulfate, or nile blue and an acid, a reagent kit for measuring platelets comprising the reagent for measuring platelets, and a method for measuring platelets using the reagent or reagent kit.. .
Sysmex Corporation


07/02/15
20150183995 

Pearlescent pigments coated with mixed inorganic/organic layers and the production thereof


The invention relates to platelet-shaped pearlescent pigments that are coated with at least one mixed inorganic/organic layer for improving their application properties, and of these, particularly their mechanical properties, and to methods for the production thereof and to the use thereof. The said mixed inorganic/organic layer comprises at least one at least partially crosslinked inorganic metal-oxide component and an organic component.
Eckart Gmbh


06/25/15
20150180073 

Ion-conducting membrane


An ion-conducting membrane includes: (i) a first ion-conducting layer including one or more first ion-conducting polymers; and (ii) a barrier layer including graphene-based platelets.. .
Johnson Matthey Fuel Cells Limited


06/25/15
20150174712 

Graphene nanoplatelet metal matrix


A metal matrix composite is disclosed that includes graphene nanoplatelets dispersed in a metal matrix. The composite provides for improved thermal conductivity.
The Boeing Company


06/25/15
20150174591 

Centrifuge


Centrifuges are useful to, among other things, remove red blood cells from whole blood and retain platelets and other factors in a reduced volume of plasma. platelet rich plasma (prp) and or platelet poor plasma (ppp) can be obtained rapidly and is ready for immediate injection into the host.
Kensey Nash Corporation


06/25/15
20150174313 

Blood component separation device


The object of the invention is to provide a blood separation device that can reduce the total time for drawing blood to obtain high-concentration platelet liquid, thereby reducing the binding time of the blood donor. The device includes a temporary storage bag (y2) (also serves as a buffy coat bag) which is a whole blood bag for storing whole blood drawn from a blood donor.
Terumo Kabushiki Kaisha


06/25/15
20150174221 

Systems, compositions, and methods for transplantation


Systems and methods for purification and concentration of autologous alpha-2-macroglobulin (a2m) from whole blood are provided. Also provided are diagnostic methods for identifying sites in the synovial joints, spine, tendons or ligaments for treatment of pain, degeneration, or inflammation with autologous a2m.
Cytonics Corporation


06/25/15
20150174171 

Compositions and methods for the treatment and alleviation of bone and cartilage diseases or injuries and hair loss


The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases or injuries and hair loss. The present invention discloses a method and a pharmaceutical composition comprising mesenchymal stem cells, platelets, activating factors and scaffolding materials for the treatment, prevention, or alleviation of bone diseases, bone injuries or hair loss, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases or injuries..

06/25/15
20150174170 

Compositions and methods for the treatment and alleviation of bone and cartilage diseases or injuries and hair loss


The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases or injuries and hair loss. The present invention discloses a method and a pharmaceutical composition comprising mesenchymal stem cells, platelets, activating factors and scaffolding materials for the treatment, prevention, or alleviation of bone diseases, bone injuries or hair loss, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases or injuries..

06/18/15
20150166760 

Metal effect pigments comprising a mixed inorganic/organic layer, the production of such metal effect pigments, and use thereof


The invention relates to metallic effect pigments with coating, comprising a platelet-shaped substrate, where the coating comprises at least one hybrid inorganic/organic layer, the hybrid layer having at least partly an inorganic network that has one or more inorganic oxide components, and having at least one organic component, the organic component being at least partly an organic oligomer and/or polymer which is covalently bonded at least partly to the inorganic network via one or more organic network formers. The invention further relates to a method of producing these metallic effect pigments, and to their use..
Eckart Gmbh


06/18/15
20150164956 

Muscle-derived cells (mdcs) for treating muscle- or bone-related injury or dysfunction


The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


06/11/15
20150160214 

Quantitation of cellular adhesion dynamics across immobilized receptors under rheological shear flow


The present invention includes an apparatus and methods for measuring cell or platelet adhesion comprising: a rheological shear flow surface coated with an agent that provides cell or platelet adhesion; a detector to track the transit of cells or platelets on the surface under shear flow; and a processor that calculates both a pause time and a roll time of platelets, wherein the processor determines a median and a mean pause time and a median and a mean roll time of cells or platelets and compares them to cells or platelets having at least one of: no cell adhesion dysfunction, a mild adhesion dysfunction, or a severe adhesion dysfunction, between a cell surface adhesion molecule on the cell or platelet and the agent, wherein the processor provides a real-time, quantitative measurement of a dynamic range of cell or platelet adhesion.. .
Mayo Foundation For Medical Education And Research


06/11/15
20150160213 

Compositions and methods for assaying platelet reactivity and treatment selection


Compositions and methods are provided for determining platelet reactivity where the levels of fcγriia on the surface of platelets is measured and if the levels of fcγriia are greater than a reference value, the platelets have enhanced reactivity.. .
The University Of Vermont And State Agriculture College


06/04/15
20150155340 

Dual-mode pixels including emissive and reflective devices, and dual-mode display using the pixels


Provided is a dual-mode display including a substrate and a plurality of sub-pixels on the substrate, in which each sub-pixel includes an emissive device, a color selection reflector disposed on one side of the emissive device, and an optical shutter disposed on another side of the emissive device, wherein the emissive device includes a cathode and an anode, and the cathode and the anode include a carbon-based material including graphene sheets, graphene flakes, and graphene platelets, and a binary or ternary transparent conductive oxide including indium oxide, tin oxide, and zinc oxide.. .
Electronics And Telecommunications Research Institute


06/04/15
20150152314 

Cement composition comprising nano-platelets


A method of cementing a subterranean formation includes providing a cement composition comprising cementitious material, aqueous base fluid, graphene nano-platelets, and a dispersant; introducing the cement composition into a subterranean formation; and allowing the cement composition to set in the subterranean formation. Upon setting, the cement has at least one of enhanced compressive and tensile strength; reduced permeability; restricted penetration of carbon dioxide; and combinations thereof relative to an equivalent cement without graphene nano-platelets.
Halliburton Energy Services, Inc.


06/04/15
20150152111 

Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition


The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.. .
Astrazeneca Uk Limited


06/04/15
20150150942 

Methods for extracting platelets and compositions obtained therefrom


This invention provides methods for extracting platelets, compositions obtained therefore, and methods for using the same.. .
The Regents Of The University Of Colorado, A Body Corporate


05/28/15
20150148901 

Apparatus and breast reconstruction and augmentation using an autologous platelet-rich fibrin matrix


Described herein are systems and methods for soft tissue reconstruction and augmentation using a platelet-rich fibrin matrix. In one embodiment the system of the present invention includes a blood collection apparatus capable of drawing blood from a patient, a matrix preparation container configured to hold a patient's blood while the blood is separated and coagulated to form a platelet-rich fibrin matrix therein, and a matrix delivery device configured to receive the matrix preparation container therein and compress and force the platelet-rich fibrin matrix out of the matrix preparation container and into the patient.

05/28/15
20150148385 

Pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity


“when the platelet count has increased by a certain amount and reached to a sufficient level of the platelet count during administration of a pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity, administration of the pharmaceutical composition is discontinued thereafter”.. .

05/28/15
20150147300 

Methods of mediating macrophage phenotypes


Methods of inducing a polarization of macrophages. The method includes obtaining a blood fraction, fractionating the blood fraction to produce a blood fraction, and contacting the blood fraction with a source of macrophages.
Biomet Biologics, Llc


05/28/15
20150147228 

Permanent magnet, and motor and generator using the same


In one embodiment, a permanent magnet has a composition represented by a composition formula: rpfeqmrcusco100-p-q-r-s, where r is a rare earth element, m is at least one element selected from zr, ti, and hf, p is 8.0 atomic % or more and 13.5 atomic % or less, q is 25 atomic % or more and 40 atomic % or less, r is 0.88 atomic % or more and 7.2 atomic % or less, and s is 3.5 atomic % or more and 13.5 atomic % or less, and a metallic structure including a cell phase having a th2zn17 crystal phase, a cell wall phase, and a platelet phase existing along a c plane of the th2zn17 crystal phase. An average thickness of the platelet phase is in a range of from 2.5 nm to 20 nm..
Kabushiki Kaisha Toshiba


05/21/15
20150141477 

Pyrazole derivatives and their use as lpar5 antagonists


The present invention relates to compounds of the formula (i), wherein the residues r1 to r5, v, g and m have the meanings indicated in the claims. The compounds of the formula (i) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses.
Sanofi


05/21/15
20150141471 

Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation


The present invention relates to compounds of the formula (i), wherein the residues r1 to r6, v, g and m have the meanings indicated in the claims. The compounds of the formula i are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses.
Sanofi


05/21/15
20150141332 

Methods for diagnosing osteoarthritis


Methods for managing osteoarthritis, in a human or other mammalian subject, comprising the measurement of certain cytokines and growth factors in a tissue sample of a subject, including one or more of platelet-derived growth factor ab (pdgf-ab), platelet-derived growth factor bb (pdgf-bb), and epidermal growth factor (egf). Tissue samples may be whole blood, blood fractions, urine, saliva, and synovial fluid.
Biomet Biologics, Llc


05/21/15
20150140120 

Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics


Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to pdgf, pdgf isoforms, pdgf receptor, vegf, and vegf receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used one or in combination with known cytotoxic agents for the treatment of solid tumors.
Archemix Llc


05/14/15
20150135344 

Methods of modulating thrombocytopenia and modified transgenic pigs


The application provides methods of modulating platelet uptake by liver sinusoidal endothelial cells and of modulating thrombocytopenia. Transgenic pigs modified to bind fewer platelets are provided..

05/14/15
20150133446 

Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation


The present invention provides imidazothiadiazole compounds of formula (i) wherein a, b, d, rx, r1, r2, r3, x1, x2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments..

05/14/15
20150132261 

Treatment of thrombocytopenia using orally administered interferon


An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of ifn (about 5 iu to about 2500 iu of ifn-alpha) to a patient in need thereof.

05/14/15
20150128935 

Inhalation systems, breathing apparatuses, and methods


Examples of the invention include inhalation systems, breathing apparatuses, and methods for administering a solution by inhalation to a patient. Example breathing apparatuses described herein may be configured to minimize loss of the solution to the environment.

05/07/15
20150126527 

Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto


The present invention relates to amide derivatives of formula (xiiia) and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah); idiopathic pah; familial pah; pah associated with a collagen vascular disease, a congenital heart disease, portal hypertension, hiv infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (pvod) or pulmonary capillary hemangiomatosis (pch); pah with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..

05/07/15
20150125436 

Process, tube and device for the preparation of wound healant composition


The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof..

05/07/15
20150125430 

Compositions and methods for inducing thrombopoiesis


Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with livin, thereby inducing thrombopoiesis.
Hadasit Medical Research Services And Development Ltd.


05/07/15
20150122713 

Prp obtaining device


A platelet rich plasma (prp) obtaining device includes a container attached to a receptacle for allowing a material in the receptacle to flow into the container, a piston engaged in the receptacle for forcing the material to partially flow into the container, a housing slidably engaged in the container and having a space and having a tube extended in the housing, the tube includes a bore communicating with a compartment of the container, but offset from the space of the housing, and a check valve is attached to the housing for limiting the material to flow only from the container to the housing, and for preventing the material from flowing backward from the housing into the container.. .
Yung Kang Medical Device & Technologic Co., Ltd.


04/30/15
20150119495 

Preparation of rubber composition containing graphite platelets and tire with component


Preparation of a rubber composition containing a dispersion of aligned exfoliated graphite platelets. Such rubber composition is prepared by a method comprised of a sequential combination of concentrated solvent or dry masterbatching of elastomer and exfoliated graphite platelets, followed by blending the masterbatch (after removing the solvent from the solvent based masterbatch) with additional elastomer(s) and then followed by processing the resulting rubber composition to align the dispersed exfoliated graphite platelets in a substantially parallel relation to each other.
The Goodyear Tire & Rubber Company


04/30/15
20150119390 

Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation


The present invention provides imidazothiadiazole compounds of formula (i); wherein w, y, r0, r2, r4, ra, rb, x1, x2, x3 and x4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders..
Universite De Monteal


04/30/15
20150118210 

Composition for enhancing cell engraftment and homing properties containing prp as active ingredient


The present invention provides a composition for enhancing cell engraftment and homing properties, containing platelet-rich plasma (prp) as an active ingredient. The present invention provides a method for improving cell engraftment and homing properties, comprising the step of treating in vitro isolated cells with a composition containing prp as an active ingredient.
Snu R&db Foundation


04/30/15
20150118109 

Component preparation system


Disclosed herein are centrifuge-free self-contained systems for aseptically separating components of whole blood comprising at least one cassette for receiving whole blood; at least one red blood cell exclusion filter; at least one leukocyte reduction filters; at least one platelet exclusion filter; a plurality of product cassettes; and optionally a plurality of pumps and valves; and wherein the filters, pumps, valves, and cassettes are fluidly connected by tubing and the system does not include a centrifuge. Also disclosed are methods for obtaining blood components using the system..
New York Blood Center, Inc.


04/23/15
20150111889 

Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists


The present invention relates to compounds of the formula (i), wherein the residues a, r1 to r5, z1 and z2 have the meanings indicated in the claims. The compounds of the formula (i) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses.
Sanofi


04/23/15
20150111777 

Biomarker for early neurodegeneration detection


The present invention relates to compositions, methods, and kits that can be used to assess neurodegeneration associated diseases and conditions in a subject by detecting the level of tdp-43 protein in platelets. The compositions, methods, and kits are suitable for neurodegeneration associated disease diagnosis, prognosis and treatment evaluation..
Kansas City University Of Medicine And Biosciences


04/16/15
20150105338 

Therapeutic compositions comprising phenolic acids for treating conditions related to inappropriate platelet aggregation


The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (i): wherein r1, r2 and r3 may be independently selected from h, oh and ome; wherein x is c1 or c2 and wherein for c2 each carbon is linked by a single or multiple bond (preferably a double bond) and is substituted with one or more h or oh, for use as a medicament for treating or preventing the development of medical conditions characterised by inappropriate platelet aggregation. The compositions of the invention may be used to maintain heart health by reducing platelet aggregation; benefit the circulation; and/or normalize or otherwise benefit blood flow..
Provexis Natural Products Limited




Popular terms: [SEARCH]

Platelet topics: Growth Factor, Fibroblast, Nanoparticle, Autologous, Leukocytes, Circulation, Transforming Growth Factor, Therapeutical, Platelet Derived Growth Factor, Bone Morphogenetic Protein, Endothelial, Recombinant, Stem Cells, Respiratory System, Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Platelet for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Platelet with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.0884

4794

459670 - 0 - 102